Navigation Links
BUSM researchers identify better laser for treating facial spider veins
Date:10/6/2009

(Boston) - Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

Telangiectasias are open (dilated) blood vessels in the outer layer of the skin usually caused by sun damage or aging. When appearing on the legs, they are often called spider veins. They are common to a number diseases, including acne, rosacea, birthmarks (port-wine stains), scleroderma, several types of inherited disorders (ataxia-telangiectasia, hereditary hemorrhagic telangiectasia, xeroderma pigmentosum, and others), or with prolonged use of oral or topical corticosteroids.

According to the researchers, while both the 532 and 940nm wavelength lasers are effective for facial telangiectasias, they lacked evidence to support whether one wavelength was superior to the other until now.

A total of 24 facial anatomic sites were treated with the 532 and the 940nm wavelength lasers. The presence and severity of side effects such as pain, erythema, crusting, swelling and blistering were assessed.

The researchers found pain associated with the laser treatment was significantly less for the 940nm wavelength compared to the 532nm wavelength. Erythema post-treatment was significantly less with 940nm relative to 532 nm. Significant crusting and swelling were only reported with the 532nm wavelength. Visual improvement with the 940nm wavelength was greater than that achieved with the 532nm wavelength. On photographic evaluation, the 940nm laser was significantly more efficacious for larger caliber vessels than 532nm. Both wavelengths were equally effective for smaller caliber vessels.

"The 940nm diode laser was found to have greater efficac
'/>"/>

Contact: Gina M. DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
2. Researchers find demand for cosmetic and surgical procedures in dermatologic surgery rising rapidly
3. Using synthetic evolution to study the brain: Researchers model key part of neurons
4. Researchers at Boston University School of Medicine incorporate multisite geriatric clerkship
5. Researchers use computational models to study fear
6. Researchers develop an integrated treatment for veterans with chronic pain and posttraumatic stress
7. UT Houston, Jamaica researchers launch autism study
8. Paul Marks prize recognizes 3 young cancer researchers
9. Van Andel Institute researchers find gene that could lead to new therapies for bone marrow disease
10. Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery
11. U of T researchers create microchip that can detect type and severity of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... global pharmaceutical giant Novartis bagged the contract to make ... vaccines. The $54.8 million contract// was finalised on Wednesday. ... million in federal contracts to fight a possible bird-flu ... also awarded contracts on Wednesday by the U.S. Department ...
... participate in a five-year study, to evaluate the risks of ... . ,Professor Lawrie Challis, an authority on mobile ... the Department of Health and the mobile phone industry. If ... of the study, which is expected to cost ?3 million. ...
... corporate downsizing not only affects those who lose jobs ... ,'Employees who remained in work after downsizing may ... said lead author Mika Kivimaki, from the Department of ... ,'In other words, enforced redundancies may boost mental ...
... failure, says a new study. // ,Gregg Fonarow ... of over 100,000 patients hospitalised because their heart condition was ... ,They found that the fatter the person, the less likely ... researchers reported their findings in the latest issue of the ...
... world were infected by HIV in each day of the year ... total, around 410,000 to 660,000 children under the age of 15 ... ,The report added that most of the children were infected ... half of the children infected last year would die of AIDS-related ...
... are becoming an increasingly important method for detecting malaria. ... a range of other strategies for controlling the disease ... insecticide-treated bed nets, indoor spraying against malaria-carrying mosquitoes and ... ,The tests are ideal for rural areas ...
Cached Medicine News:Health News:Downsizing Affects All Workers 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... PRA International, a leading Clinical Research Organization, announces that ... Annual Partnerships in Clinical Trials 2009 to be held 4 ... Rotterdam, The Netherlands. PRA operational and therapeutic leaders are ... number 32. , On 4 November, PRA,s Christian Tucat, Senior ...
... announces results for,the three months to September 30, 2009. , , Q3 2009 Financial Highlights, ... ... ... $532 million +20%, Product sales ...
Cached Medicine Technology:PRA International Experts Present a Session at the 8th Annual Partnerships in Clinical Trials 2009 2Shire Continues to Deliver Excellent Growth From Core Products 2Shire Continues to Deliver Excellent Growth From Core Products 3Shire Continues to Deliver Excellent Growth From Core Products 4Shire Continues to Deliver Excellent Growth From Core Products 5Shire Continues to Deliver Excellent Growth From Core Products 6Shire Continues to Deliver Excellent Growth From Core Products 7Shire Continues to Deliver Excellent Growth From Core Products 8Shire Continues to Deliver Excellent Growth From Core Products 9Shire Continues to Deliver Excellent Growth From Core Products 10Shire Continues to Deliver Excellent Growth From Core Products 11Shire Continues to Deliver Excellent Growth From Core Products 12Shire Continues to Deliver Excellent Growth From Core Products 13Shire Continues to Deliver Excellent Growth From Core Products 14Shire Continues to Deliver Excellent Growth From Core Products 15Shire Continues to Deliver Excellent Growth From Core Products 16Shire Continues to Deliver Excellent Growth From Core Products 17Shire Continues to Deliver Excellent Growth From Core Products 18Shire Continues to Deliver Excellent Growth From Core Products 19Shire Continues to Deliver Excellent Growth From Core Products 20Shire Continues to Deliver Excellent Growth From Core Products 21Shire Continues to Deliver Excellent Growth From Core Products 22Shire Continues to Deliver Excellent Growth From Core Products 23Shire Continues to Deliver Excellent Growth From Core Products 24Shire Continues to Deliver Excellent Growth From Core Products 25Shire Continues to Deliver Excellent Growth From Core Products 26Shire Continues to Deliver Excellent Growth From Core Products 27Shire Continues to Deliver Excellent Growth From Core Products 28Shire Continues to Deliver Excellent Growth From Core Products 29Shire Continues to Deliver Excellent Growth From Core Products 30Shire Continues to Deliver Excellent Growth From Core Products 31Shire Continues to Deliver Excellent Growth From Core Products 32Shire Continues to Deliver Excellent Growth From Core Products 33
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
... series slit lamp biomicroscopy ... of the posterior pole. ... capability, specifically addressing maximum ... fundus image resolution & ...
Volk indirect lenses. High magnification views of the posterior pole....
Medicine Products: